Cargando…
Fibroblast growth-factor-21 is currently a weak biomarker for identifying mitochondrial and non-mitochondrial inborn errors of metabolism
Autores principales: | Finsterer, Josef, Zarrouk-Mahjoub, Sinda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671407/ https://www.ncbi.nlm.nih.gov/pubmed/29124013 http://dx.doi.org/10.1016/j.ymgmr.2017.10.005 |
Ejemplares similares
-
Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed()()()()
por: Finsterer, Josef, et al.
Publicado: (2017) -
Biomarkers for Detecting Mitochondrial Disorders
por: Finsterer, Josef, et al.
Publicado: (2018) -
Anti-mitochondrial M2 Antibodies and Myopathy
por: Finsterer, Josef, et al.
Publicado: (2017) -
Letter to the Editor: Endocrine Compromise in Mitochondrial Disorders
por: Finsterer, Josef, et al.
Publicado: (2018) -
Mitochondrial cardioencephalopathy due to a COQ4 mutation
por: Finsterer, Josef, et al.
Publicado: (2017)